Patient Groups Recognize Lundbeck as a Top Company for Corporate Reputation for 6th Straight Year

Annual survey finds patient organizations identify Lundbeck US as a leader in patient centricity and #1 in corporate reputation among companies focused on brain health

Deerfield, Ill. – May 13, 2021 – For the sixth straight year, patient groups recognized Lundbeck US, an affiliate of the global pharmaceutical company H. Lundbeck A/S, among the top life science companies for corporate reputation. According to the new PatientView Corporate Reputation of Pharma, USA Edition, Lundbeck US ranked in the top tier for corporate reputation, and #1 in both overall reputation and patient support during the COVID-19 crisis among companies focused on brain health.

“To be recognized for our commitment to patients is an honor, and to be ranked as a top company six consecutive years—including five years as #1—speaks to the effort we put into sustaining a patient-centric culture,” said Peter Anastasiou, Lundbeck executive vice president and head of North America. “Our approach to patient-group engagement is never stagnant because our communities’ needs are continuously evolving. At every level and within every function, we work to engage our patient communities in different and meaningful ways so that we can better understand their needs and focus the work we do. Keeping the patient’s perspective forefront in our minds ensures we are addressing challenges that patients say matter most.”

Report highlights

The PatientView report, which is based on a survey of 207 U.S. patient groups, compiles feedback on the performance of pharmaceutical companies on key indicators of corporate reputation. In addition to ranking among top companies for overall reputation, Lundbeck also was ranked in the highest tier for 12 individual reputational categories, including:

• Patient centricity
• Integrity
• Quality of patient-group relationships
• “Beyond-the-pill” services

Response to extraordinary times

New this year, the survey also asked patient groups to assess pharmaceutical companies on the contributions that companies made to alleviating problems imposed by the pandemic on non-COVID patients. Lundbeck is particularly proud of being ranked as a top company in this category because of the efforts made over the course of 2020 to ensure a continued focus on the unique needs of people with brain diseases. COVID-related support included:

• Utilizing technology and big data to identify mental illness hotspots. When the mental health impacts of the pandemic first started appearing in spring 2020, Lundbeck committed to playing a leading role flattening this “second curve.” The company teamed with Mental Health America (MHA) on a groundbreaking initiative that will help identify mental illness hotspots emerging from the pandemic. The bold initiative will analyze the extensive data set generated by MHA’s online mental health screenings, plus publicly available screening data sets, to create a nationwide mental health dashboard. Real-time analysis will allow communities to identify hotspots and react quickly; and the population-based insights can help policymakers, communities and health care providers allocate the right resources, address health disparities and tailor interventions as needed.
• Keeping communities connected, even when physically apart. In partnership with patient advocacy group partners, Lundbeck shared resources and information to help people who may be struggling with social isolation and mental health impacts of the pandemic. The company collaborated with patient groups representing neurological disorders like Parkinson’s disease and migraine to help people understand how they could stay connected with normal support networks during challenging times.
• Addressing racial inequities. Lundbeck also took steps to address racial disparities in healthcare—disparities that were highlighted by the pandemic’s disproportionate toll on communities of color. Working in collaboration with migraine and mental health patient groups, the company initiated action to help understand and address barriers to mental health treatment and migraine care. 

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global biopharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

Our approximately 6,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France and Italy.

In the U.S., Lundbeck employs approximately 1,000 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support our patient communities.

For additional information, we encourage you to visit at www.lundbeckus.com, subscribe to our newsletter at Newsroom.LundbeckUS.com and connect with us on Twitter at @LundbeckUS.

Lundbeck Media Contact:

Molly Brennan
Associate Director, Corporate Communications
mlly@lundbeck.com